Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Diagnostic Efficiency Of68ga-Dotatate Pet/Ct As Compared To99mtc-Octreotide Spect/Ct and Conventional Morphologic Modalities in Neuroendocrine Tumors Publisher



Fallahi B1 ; Manafifarid R1 ; Eftekhari M1 ; Fardesfahani A1 ; Emamiardekani A1 ; Geramifar P1 ; Akhlaghi M1 ; Taheri APH2 ; Beiki D1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Research Center for Nuclear Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Radiology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran

Source: Asia Oceania Journal of Nuclear Medicine and Biology Published:2019


Abstract

Objective(s): In view of somatostatin receptor (SSR) expression on cell membranes of the majority of neuroendocrine tumors (NETs), functional imaging exploiting analogs of SSR alongside the anatomical imaging is the mainstay of this diagnostic modality. In this prospective study, we assessed and directly compared the diagnostic parameters of68Ga-DOTATATE PET/CT and99mTc-Octreotide SPECT/CT, as well as CT/MRI. Methods: Twenty-five NET patients, either histologically proven or highly suspicious for NET, who were referred for Octreotide Scan were enrolled in this prospective study. They all underwent99mTc-Octreotide SPECT/CT and then68Ga-DOTATATE PET/CT. A blind interpretation was conducted for each imaging as well as for the previously obtained conventional imaging (CT or MRI). The patient-based and lesion-based analysis were conducted and the results of the three modalities were compared. The histopathologic confirmation or follow-up data were considered as the gold standard. Also, the impact of68Ga-DOTATATE PET/CT on the patient’s management was assessed. Results: Overall, 77 lesions in 14 patients, 135 in 19 and 86 in 16 were detected on99mTc-Octreotide SPECT/CT,68Ga-DOTATATE PET/CT and CT/MRI, respectively. On patient-based analysis, the sensitivity was 65%, 90% and 71% for99mTc-Octreotide SPECT/CT,68Ga-DOTATATE PET/CT and CT/MRI, respectively. Also, the specificity was 80%, 80% and 75% for99mTc-Octreotide SPECT/CT,68Ga-DOTATATE PET/CT and CT/MRI, respectively. The correlation between68Ga-DOTATATE PET/CT and99mTc-Octreotide SPECT/CT results was significant (P=0.02; kappa value=0.57), no correlation, however, was depicted with CI (P=0.07; kappa value=0.35). On lesion-based analysis,68Ga-DOTATATE PET/CT found more organs (P=0.02) and lesions (P=0.001) in comparison with99mTc-Octreotide SPECT/CT and also more lesions in comparison with CT/MRI (P=0.003). In addition, comparing with99mTc-Octreotide SPECT/CT and CT/MRI,68Ga-DOTATATE PET/CT revealed more data in 44% and 36% of the patients, resulting in management modification in 24% and 20%, respectively. Conclusion: Comparing with99mTc-Octreotide SPECT/CT and CT/MRI,68Ga- DOTATATE PET/CT provided more sensitivity and specificity in patients with NETs showing more involved organs as well as tumoral lesions. Also,68Ga-DOTATATE PET/ CT led to change of management in up to one-fourth of the patients, especially in a sub-group re-evaluated for recurrence. © 2019 mums.ac.ir All rights reserved.